On 31 July 2020 CLINUVEL Pharmaceutical Limited (ASX:CUV) reported its 4Q FY20 update.
In the fourth quarter of FY20, cash flow remained positive, and CLINUVEL has A$66.747 million cash at hand rise of A$4.42 million.
During this quarter, CLINUVEL recorded cash receipts of A$10.4 million. Despite the ongoing COVID-19 pandemic, CLINUVEL has extended access to SCENESSE® during FY20.
Cash and equivalents of the company rose by 7% over the quarter.
Subsequent to SCENESSE® approval in Europe and the US, CLINUVEL is pursuing approvals for EPP in other regions, and the decision is anticipated from the TGA by the end of CY20.